Clinical Trial Update: Safety of RG2077 in Patients With Multiple Sclerosis [Phase 1]

View source ↗

Summary

Phase 1 safety update reporting on RG2077 in patients with multiple sclerosis, including relapsing-remitting multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• RG2077 (RG2077)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 1 | Status: COMPLETED